About AtriCure (NASDAQ:ATRC)
AtriCure, Inc. is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. It has two primary product lines for cardiac tissue ablation, which include Radio Frequency Ablation Devices and cryoICE Cryoablation System, and a product line for left atrial appendage exclusion. The Company also sells Lumitip dissectors and the Estech line of reusable cardiac surgery (valve) instruments. Its cryoICE cryosurgery product line offers various cryoablation devices. Its AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart's left atrial appendage (LAA).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment, Supplies & Distribution
- Sub-Industry: Health Care Equipment
- Symbol: NASDAQ:ATRC
- CUSIP: 04963C20
- Web: www.atricure.com
- Market Cap: $783.85 million
- Outstanding Shares: 34,334,000
- 50 Day Moving Avg: $21.97
- 200 Day Moving Avg: $22.04
- 52 Week Range: $14.78 - $25.18
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -32.15
- P/E Growth: -1.21
- Annual Revenue: $166 million
- Price / Sales: 4.72
- Book Value: $4.70 per share
- Price / Book: 4.86
- EBITDA: ($19,620,000.00)
- Net Margins: -19.56%
- Return on Equity: -19.56%
- Return on Assets: -11.91%
- Debt-to-Equity Ratio: 0.21%
- Current Ratio: 2.56%
- Quick Ratio: 1.93%
- Average Volume: 198,020 shs.
- Beta: 0.84
- Short Ratio: 13.26
Frequently Asked Questions for AtriCure (NASDAQ:ATRC)
What is AtriCure's stock symbol?
AtriCure trades on the NASDAQ under the ticker symbol "ATRC."
How were AtriCure's earnings last quarter?
AtriCure, Inc. (NASDAQ:ATRC) posted its quarterly earnings data on Thursday, July, 27th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.26) by $0.05. The firm had revenue of $45.23 million for the quarter, compared to the consensus estimate of $44.15 million. AtriCure had a negative return on equity of 19.56% and a negative net margin of 19.56%. The business's revenue for the quarter was up 14.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.26) EPS. View AtriCure's Earnings History.
When will AtriCure make its next earnings announcement?
What guidance has AtriCure issued on next quarter's earnings?
AtriCure updated its FY17 earnings guidance on Thursday, July, 27th. The company provided earnings per share guidance of $(1.04)-(0.94) for the period, compared to the Thomson Reuters consensus estimate of ($0.96). The company issued revenue guidance of $177-178 million, compared to the consensus revenue estimate of $175.85 million.
Where is AtriCure's stock going? Where will AtriCure's stock price be in 2017?
7 brokerages have issued twelve-month target prices for AtriCure's shares. Their forecasts range from $24.00 to $28.00. On average, they anticipate AtriCure's stock price to reach $25.83 in the next year. View Analyst Ratings for AtriCure.
What are analysts saying about AtriCure stock?
Here are some recent quotes from research analysts about AtriCure stock:
- 1. According to Zacks Investment Research, "AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure, Inc. bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, a quivering of the upper chambers of the heart. " (10/2/2017)
- 2. Needham & Company LLC analysts commented, "ATRC’s 2Q17 revenue, EBITDA, and EPS beat consensus and management raised its 2017 revenue guidance. Worldwide Open-Heart Ablation growth improved to 11% from 10% in 1Q17 and US Open-Heart Ablation growth improved to 14% from 12% in 1Q17. We think that the accelerating Open-Heart growth should help to reduce concerns that this business is in a permanent slowdown and we think this shows that the new guidelines for ablation in concomitant open-heart procedures are driving stronger growth in this business. ATRC shares remain at a large discount to peers (2017E EV/sales of 4.4x vs. small/mid-cap growth peers at a median of 7.1x) and we reiterate our Buy rating." (7/28/2017)
Who are some of AtriCure's key competitors?
Some companies that are related to AtriCure include MiMedx Group (MDXG), CONMED Corporation (CNMD), Asante Solutions (PUMP), OraSure Technologies (OSUR), Orthofix International N.V. (OFIX), Intersect ENT (XENT), Cardiovascular Systems (CSII), K2M Group Holdings (KTWO), CryoLife (CRY), Meridian Bioscience (VIVO), Landauer (LDR), Consort Medical plc (CSRT), STAAR Surgical Company (STAA), Transenterix (TRXC), Transenterix (TRXC), Invacare Corporation (IVC), Exactech (EXAC) and Antares Pharma (ATRS).
Who are AtriCure's key executives?
AtriCure's management team includes the folowing people:
- Richard M. Johnston, Independent Chairman of the Board
- Michael H. Carrel, President, Chief Executive Officer, Director
- M. Andrew Wade CPA, Chief Financial Officer, Senior Vice President
- Douglas J. Seith, Chief Operating Officer
- Justin J. Noznesky, Senior Vice President, Marketing and Business Development
- Andrew L. Lux Ph.D., Senior Vice President -Operations and Quality
- Salvatore Privitera, Chief Technology Officer
- Mark A. Collar, Independent Director
- Scott William Drake, Independent Director
- Regina E. Groves, Independent Director
How do I buy AtriCure stock?
Shares of AtriCure can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AtriCure's stock price today?
MarketBeat Community Rating for AtriCure (NASDAQ ATRC)MarketBeat's community ratings are surveys of what our community members think about AtriCure and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of AtriCure stock can currently be purchased for approximately $22.83.
Consensus Ratings for AtriCure (NASDAQ:ATRC) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Hold Rating, 6 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.86)|
|Consensus Price Target: ||$25.83 (13.16% upside)|Consensus Price Target History for AtriCure (NASDAQ:ATRC)
Analysts' Ratings History for AtriCure (NASDAQ:ATRC)
(Data available from 10/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/9/2017||Canaccord Genuity||Reiterated Rating||Buy||$28.00||N/A|
|7/30/2017||Stifel Nicolaus||Reiterated Rating||Buy||$25.00||Medium|
|7/28/2017||Needham & Company LLC||Reiterated Rating||Buy -> Buy||$25.00 -> $26.00||High|
|6/16/2017||Leerink Swann||Reiterated Rating||Outperform||$26.00||Low|
|5/30/2017||Piper Jaffray Companies||Reiterated Rating||Overweight -> Overweight||$26.00||Low|
|3/20/2017||Northland Securities||Reiterated Rating||Buy||$24.00||Low|
|3/6/2017||BTIG Research||Downgrade||Buy -> Neutral||N/A|
|8/6/2016||JMP Securities||Set Price Target||Buy||$23.00||N/A|
Earnings History for AtriCure (NASDAQ:ATRC)Earnings History by Quarter for AtriCure (NASDAQ ATRC)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|7/27/2017||Q2 2017||($0.26)||($0.21)||$44.15 million||$45.23 million||View||N/A|
|5/4/2017||Q1 2017||($0.33)||($0.32)||$40.25 million||$41.30 million||View||Listen|
|2/28/2017||Q4 2016||($0.32)||($0.27)||$41.17 million||$41.20 million||View||Listen|
|10/27/2016||Q316||($0.28)||($0.21)||$10.75 million||$38.34 million||View||Listen|
|8/4/2016||Q216||($0.30)||($0.26)||$39.84 million||$39.70 million||View||Listen|
|4/28/2016||Q116||($0.32)||($0.31)||$36.08 million||$35.90 million||View||Listen|
|2/23/2016||Q415||($0.36)||($0.36)||$35.90 million||$35.90 million||View||Listen|
|10/27/2015||Q315||($0.22)||($0.22)||$31.32 million||$31.40 million||View||Listen|
|7/28/2015||Q215||($0.21)||($0.18)||$30.51 million||$32.58 million||View||Listen|
|4/29/2015||Q115||($0.21)||($0.19)||$28.65 million||$29.90 million||View||Listen|
|2/23/2015||Q414||($0.20)||($0.20)||$28.40 million||$29.40 million||View||Listen|
|10/30/2014||Q314||($0.17)||($0.02)||$25.60 million||$26.70 million||View||Listen|
|7/24/2014||Q214||($0.19)||($0.10)||$25.03 million||$26.51 million||View||Listen|
|4/24/2014||Q114||($0.22)||($0.31)||$23.36 million||$24.80 million||View||Listen|
|2/27/2014||Q413||($0.14)||($0.24)||$21.16 million||$21.90 million||View||Listen|
|10/29/2013||Q313||($0.15)||($0.13)||$18.30 million||$20.10 million||View||Listen|
|8/1/2013||Q2 2013||($0.10)||($0.09)||$19.42 million||$20.40 million||View||Listen|
|5/2/2013||Q1 2013||($0.09)||($0.10)||$18.63 million||$19.43 million||View||Listen|
|2/28/2013||Q4 2012||($0.09)||($0.12)||$18.46 million||$18.40 million||View||Listen|
|11/1/2012||Q312||($0.11)||($0.16)||$17.29 million||$16.10 million||View||N/A|
Earnings Estimates for AtriCure (NASDAQ:ATRC)
2017 EPS Consensus Estimate: ($1.09)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for AtriCure (NASDAQ:ATRC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for AtriCure (NASDAQ:ATRC)
Insider Ownership Percentage: 10.00%Insider Trades by Quarter for AtriCure (NASDAQ:ATRC)
Institutional Ownership Percentage: 82.11%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/22/2017||Elizabeth D Krell||Director||Sell||10,000||$22.40||$224,000.00|| |
|5/17/2017||Elizabeth D Krell||Director||Sell||10,000||$21.44||$214,400.00|| |
|3/17/2017||Andrew L Lux||SVP||Sell||20,000||$18.85||$377,000.00|| |
|11/15/2016||Elizabeth D Krell||Director||Sell||10,000||$19.73||$197,300.00|| |
|9/13/2016||Elizabeth D Krell||Director||Sell||6,000||$15.93||$95,580.00|| |
|8/17/2016||Elizabeth D Krell||Director||Sell||5,000||$15.20||$76,000.00|| |
|3/8/2016||Elizabeth D Krell||Director||Sell||10,000||$16.91||$169,100.00|| |
|12/3/2015||Douglas J. Seith||COO||Sell||5,000||$21.55||$107,750.00|| |
|12/2/2015||Elizabeth D. Krell||Director||Sell||10,000||$21.88||$218,800.00|| |
|11/11/2015||Elizabeth D. Krell||Director||Sell||10,000||$20.68||$206,800.00|| |
|4/1/2015||Michael D Hooven||Director||Sell||142,268||$20.81||$2,960,597.08|| |
|3/31/2015||Michael D Hooven||Director||Sell||20,000||$20.51||$410,200.00|| |
|3/30/2015||Michael D Hooven||Director||Sell||85,000||$21.01||$1,785,850.00|| |
|3/13/2015||Karen P Robards||Director||Sell||3,150||$19.53||$61,519.50|| |
|3/5/2015||Douglas J Seith||COO||Sell||36,688||$17.51||$642,406.88|| |
|3/2/2015||Elizabeth D Krell||Director||Sell||10,000||$17.63||$176,300.00|| |
|5/6/2014||Douglas Seith||SVP||Buy||1,000||$15.04||$15,040.00|| |
|9/13/2013||Richard Johnston||Insider||Sell||77,610||$10.00||$776,100.00|| |
|8/12/2013||Douglas Seith||SVP||Buy||10,000||$9.58||$95,800.00|| |
|8/5/2013||Richard Johnston||Insider||Sell||20,047||$10.00||$200,470.00|| |
|7/11/2013||Richard M Johnston||Insider||Sell||2,343||$10.00||$23,430.00|| |
|6/19/2013||Richard M Johnston||Insider||Sell||29,348||$8.96||$262,958.08|| |
|6/18/2013||Richard M Johnston||Insider||Sell||39,682||$9.18||$364,280.76|| |
|6/14/2013||Richard M Johnston||Insider||Sell||95,598||$8.97||$857,514.06|| |
|6/12/2013||Richard M Johnston||Insider||Sell||35,372||$9.01||$318,701.72|| |
|3/6/2013||James L Lucky||VP||Sell||50,065||$8.14||$407,529.10|| |
|9/14/2012||Mark R Lanning||Director||Buy||11,006||$7.64||$84,085.84|| |
|9/13/2012||Michael D Hooven||Director||Buy||1,110||$7.37||$8,180.70|| |
|9/12/2012||Michael D Hooven||Director||Buy||1,150||$7.10||$8,165.00|| |
|9/11/2012||Michael D Hooven||Director||Buy||1,145||$7.18||$8,221.10|| |
|9/10/2012||Michael D Hooven||Director||Buy||1,215||$7.15||$8,687.25|| |
|9/7/2012||Michael D Hooven||Director||Buy||1,215||$6.88||$8,359.20|| |
|8/23/2012||Karen P Robards||Director||Buy||1,000||$6.70||$6,700.00|| |
|8/16/2012||Karen P Robards||Director||Buy||1,000||$6.98||$6,980.00|| |
Headline Trends for AtriCure (NASDAQ:ATRC)
Latest Headlines for AtriCure (NASDAQ:ATRC)
Loading headlines, please wait.
AtriCure (ATRC) Chart for Sunday, October, 22, 2017